Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06197568
Other study ID # GSM-201
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2024
Est. completion date December 2024

Study information

Verified date December 2023
Source Azure Biotech Inc.
Contact Howard Levy, MD PhD
Phone (848) 992-5888
Email hlevy@hlevyconsulting.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study Objectives: Primary ° To evaluate the safety and tolerability of multiple vaginal doses of AZU-101 at 3 dose levels in postmenopausal women Secondary - To assess systemic pharmacokinetics (PK) of AZU-101 - To assess the efficacy of multiple vaginal doses of AZU-101 at 3 dose levels in postmenopausal women


Description:

This is an open-label Phase 1b/2a study to evaluate the safety, pharmacokinetics (PK), and efficacy of vaginal AZU-101 in healthy postmenopausal female subjects over a period of 28 days. AZU-101 is a vaginal formulation of lasofoxifene tartrate, a selective estrogen receptor modulator (SERM). A total of 35 subjects, age 45 to 65 years, will be assigned to five cohorts (Cohorts 1-5) sequentially during enrollment (n=7/cohort). A once-weekly dose of AZU-101 will be administered at a dose of 0.1 μg (Cohort 1), 0.5 μg (Cohort 2), or 1 μg (Cohort 3) for 4 doses. A twice-weekly dose of AZU-101 will be administered at a dose of 0.1 μg (Cohort 4) or 0.5 μg (Cohort 5) for 8 doses. Safety and tolerability will be measured by vital signs, electrocardiogram (ECG) parameters, and the incidence of Treatment-Emergent Adverse Events (TEAEs) and concomitant treatments. The PK profile will be assessed using peak plasma concentration (Cmax), time to peak plasma concentration (tmax), and area-under-the-concentration-time-curve from time zero to infinity (AUC0-∞). Efficacy will be evaluated using vaginal pH, the vaginal Maturation Index (percentage of vaginal parabasal cells and superficial cells), and identification of the most bothersome symptom to the subject (dyspareunia, vaginal dryness, or vaginal irritation/itching).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 35
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria: 1. Postmenopausal female subjects between 45 and 65 years old, inclusive (at the time of signing informed consent) with at least: 1. 12 months of spontaneous amenorrhea; or 2. At least 6 weeks postsurgical bilateral oophorectomy. 2. Have self-identified at least one moderate to severe vaginal symptom that is most bothersome to her: 1. Pain associated with sexual activity (dyspareunia) 2. Vaginal dryness 3. Vaginal irritation/itching 3. Vaginal pH =5. 4. Vaginal smear with the percentage of superficial cells not exceeding 5% 5. In the opinion of the Investigator, the subject will comply with the protocol and has a high probability of completing the study. Exclusion Criteria: 1. Any contraindication to SERMs 2. Use of any of the following: 1. Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 3 months before Screening Visit 2. Transdermal hormone products within 4 weeks before Screening Visit 3. Vaginal hormone products (rings, creams, gels) within 4 weeks before Screening Visit 4. Intrauterine progestins within 8 weeks before Screening Visit 5. Progestin implants/injectables or estrogen pellets/injectables within 6 months before Screening Visit 6. Any medication, herbal product or nutritional supplement known or suspected to interact with AZU-101 within 2 weeks prior to Screening Visit 3. Evidence of underlying disease during the Screening Visit (performed within 28 days of Day 1) or at admission on Day 1. 4. A history or active presence of clinically important medical disease that might confound the study or be detrimental to the subject, including but not limited to: 1. Endometrial hyperplasia 2. Undiagnosed vaginal bleeding 3. History of a chronic liver or kidney dysfunction/disorder (e.g., hepatitis C or chronic renal failure) 4. Thrombophlebitis, thrombosis, or thromboembolic disorders 5. Cerebrovascular accident, stroke, or transient ischemic attack 6. Myocardial infarction or ischemic heart disease 7. Malignancy or treatment for malignancy, within the previous 5 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin 8. History of estrogen dependent neoplasia, breast cancer, melanoma, or any gynecologic cancer, at any time 9. Endocrine disease (except for controlled hypothyroidism or controlled non-insulin dependent diabetes mellitus) 10. Known breast cancer gene (BRCA) mutation associated with increased risk of neoplasia 5. TVUS of the endometrium at Screening with a double-wall thickness measurement greater than 4 mm 6. Abnormal endometrial biopsy in non-hysterectomized women 7. A body mass index (BMI) <18 and >38 kg/m2 8. History of known alcohol or drug abuse within 1 year of the Screening Visit 9. Positive urine drug or alcohol screen at Screening Visit 10. Use of 15 or more cigarettes per day or current use of any electronic cigarettes 11. Use of an investigational drug or biologic within 60 days before administration of the first dose of study drug 12. Any clinically important abnormalities on Screening physical examination, assessments, ECG, or laboratory tests, including but not limited to: 1. Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS). Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, cervical intraepithelial neoplasia (CIN) grade 1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative or she has a history of vaccination against HPV. 2. Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result (Breast Imaging Reporting and Data System [BI-RADS] category 0) or unresolved findings suggestive of malignant changes or findings requiring short interval follow-up on the pre-study mammogram (subjects must have mammography result of BI-RADS category 1 or 2 to enroll). Mammogram performed within 9 months prior to Screening Visit with documentation available may be used to evaluate study eligibility. The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment. 3. Hematocrit <35% or >45% 4. Serum creatinine >15% of the upper limit of normal (ULN) for the laboratory used. 5. Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) >1.5 times the ULN for the laboratory used 6. Fasting total cholesterol greater than 300 mg/dL (7.77 mmol/L) or triglycerides greater than 300 mg/dL (3.39 mmol/L) 7. Positive laboratory finding for Factor V Leiden mutation 8. Fasting glucose >125 mg/dL 9. Uncontrolled hypertension (subjects with sitting BP >139 mmHg systolic or >89 mmHg diastolic) and may not be using more than 2 antihypertensive medications for the treatment of hypertension 10. Uncontrolled hypotension; subjects with sitting BP <95 mmHg systolic or <65 mmHg diastolic 11. A clinically significant abnormal 12-lead ECG (e.g., showing previous myocardial infarction or other findings suggestive of ischemia) 12. Positive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lasofoxifene Tartrate (AZU-101)
0.1 µg vaginal dose of AZU-101 weekly for 4 doses
Lasofoxifene Tartrate (AZU-101)
0.5 µg vaginal dose of AZU-101 weekly for 4 doses
Lasofoxifene Tartrate (AZU-101)
1 µg vaginal dose of AZU-101 weekly for 4 doses
Lasofoxifene Tartrate (AZU-101)
0.1 µg vaginal dose of AZU-101 twice-weekly for 8 doses
Lasofoxifene Tartrate (AZU-101)
0.5 µg vaginal dose of AZU-101 twice-weekly for 8 doses

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Azure Biotech Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Had Any Serious Adverse Events or Any Treatment Emergent Adverse Events With Severity Greater Than "Moderate" as measured by CTCAE v4.0 Number of participants who had any serious adverse events or any adverse events with severity greater than "moderate," as determined by the Principal Investigator, using the composite safety assessment including clinical laboratory testing (full blood count, biochemistry, coagulation, lipid panel, thyroid hormone, urinalysis), ECG, vital signs, physical examination, transvaginal ultrasound, endometrial biopsy, and self-reporting of adverse events that are determined to be clinically significant. 28 days
Secondary Pharmacokinetics (Cmax) Peak plasma concentration in pg/mL 24 hours after day 1
Secondary Pharmacokinetics (Tmax) Time to peak plasma concentration in hours 24 hours after day 1
Secondary Pharmacokinetics (AUC0-8) Area under the concentration versus time curve in pg*hr/mL 24 hours after day 1
Secondary Pharmacokinetics (Cmax) Peak plasma concentration in pg/mL 24 hours after day 21
Secondary Pharmacokinetics (Tmax) Time to peak plasma concentration in hours 24 hours after day 21
Secondary Pharmacokinetics (AUC0-8) Area under the concentration versus time curve in pg*hr/mL 24 hours after day 21
Secondary Efficacy (Vaginal pH) Vaginal pH 28 days
Secondary Efficacy (Maturation index) Ratio of percentage of superficial cells to percentage of basal cells 28 days
Secondary Efficacy (symptoms) Change from baseline of the most bothersome symptom, as reported by the subject (pain associated with sexual activity, vaginal dryness, or vaginal irritation/itching), graded as 0=none; 1=mild; 2=moderate; 3=severe; range 0 to 3. Efficacy outcome will be proportion of subjects who improve at least one grade 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06369363 - Estrogen Deficiency on Cardiovascular Risk Early Phase 1
Not yet recruiting NCT01170195 - Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms Phase 1/Phase 2
Completed NCT00535288 - Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) Phase 3
Recruiting NCT06030388 - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women N/A
Not yet recruiting NCT05557799 - Photobiomodulation in Post Menopause Genitourinary Syndrome Phase 1/Phase 2
Recruiting NCT04893226 - Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women N/A
Completed NCT03684096 - Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes N/A
Completed NCT01268046 - Aging and Estrogen on Cortical Function Phase 1/Phase 2
Recruiting NCT05659693 - The Effect of Digital Literacy Education Given to Postmenopausal Women on Health Literacy and Quality of Life N/A
Completed NCT03572153 - A Mind-Body Intervention for Hot Flash Management N/A
Not yet recruiting NCT06419972 - Multimodal Program for Climacteric Women N/A
Withdrawn NCT03854396 - Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Phase 3
Completed NCT01361308 - Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) Phase 3
Unknown status NCT00905723 - The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women Phase 3
Recruiting NCT05351476 - Exercise Training and Fat Metabolism in Postmenopausal Women N/A
Completed NCT06096818 - Kegel and Abdominal Exercises on Urinary Incontinence Severity, Quality of Life, and Sleep Quality in Menopausal Women N/A
Completed NCT03150407 - Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness N/A
Recruiting NCT06220266 - Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phase 2/Phase 3
Recruiting NCT04129060 - Cholinergic Health After Menopause (CHAMP) Early Phase 1
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A